UK headquartered health-tech company Medopad is to expand into the US.
It will occupy up a new office in the heart of New York City at Johnson & Johnson’s new JLABS office.
The JLABS model is specifically designed to help life science entrepreneurs gain access to the equipment, mentors, resources and experiences they need to bring their companies forward.
As part of its US launch, Medopad plans to hire top healthtech talent before the end of the year.
New York City is an established nucleus for the life sciences industry, home to the largest concentration of academic institutions in the world. Also, New York boasts the largest workforce in bioscience across the country working at more than 120 companies.
Dan Vahdat, CEO of Medopad, said: “We are thrilled to open a base in the USA as part of Johnson & Johnson’s incubator platform JLABS. This is a fantastic opportunity for Medopad as our values and vision are aligned with J&J’s leadership to help create a world where people can live longer. We value this partnership are looking forward to moving into our new office”.
“We have been working in partnership with US pharmaceuticals, healthcare providers and academic institutions such as Johns Hopkins where Medopad is used to connect clinicians to patients remotely and collect real world evidence. We look forward to strengthening these bonds and driving more innovative change for better health outcomes for people. The remote patient monitoring market is more than 8 times bigger in the US vs UK.”
Vahdat added: “The healthcare industry is highly-regulated and deeply complex, change is slower than is needed. Our disruptive healthcare patient monitoring solution will help bring great ideas from bench to bedside.”
Medopad recent business highlights:
– 400% growth in value of signed projects year-on-year since 2015 including: The Royal Free, Guys, St Thomas’s, GSK, Johnson & Johnson and Boston Scientific;
– Awarded Champion of the European Accenture HealthTech Innovation Challenge;
– Awarded ‘Best Healthcare Technology of the Year’ at the National Technology Awards;
– KPMG names Medopad a `US$1bn HealthTech company in the making.´
(picture: Alex Gilbert, Medopad; Johnson & Johnson CEO Alex Gorsky; and, Martha Carruthers, Medopad)
